Terms: = Leukemia AND PPFIBP1, L2, 8496, ENSG00000110841, hSGT2, hSgt2p
543 results:
1. Quantitative computed tomography analysis of body composition changes in paediatric patients with acute lymphoblastic leukaemia.
Suwannaying K; Ong AA; Dhaduk R; Pei D; Iijima M; Merkle E; Zhuang TZ; Goodenough CG; Brown J; Browne EK; Wolcott B; Cheng C; Wilson CL; Pui CH; Ness KK; Kaste SC; Inaba H
Br J Haematol; 2024 Apr; 204(4):1335-1343. PubMed ID: 38291722
[TBL] [Abstract] [Full Text] [Related]
2. RUNX1 rearrangement in mature B-cell acute lymphoblastic leukemia with non-L3 morphology.
Yamamoto K; Kitao A; Watanabe M; Kanehira H; Joyce M; Hirakawa Y; Matsumoto S; Yakushijin K; Minami H
J Clin Exp Hematop; 2023 Dec; 63(4):240-245. PubMed ID: 37899239
[TBL] [Abstract] [Full Text] [Related]
3. Increased PD-1 expression of bone marrow T-cells in acute myeloid leukaemia patients after stem cell transplantation, and its association with overall survival.
You E; Park CJ; Cho YU; Jang S; Lee MY; Kim H; Koh KN; Im HJ; Choi EJ; Lee JH; Lee KH
Ann Clin Biochem; 2024 Mar; 61(2):79-89. PubMed ID: 37314798
[TBL] [Abstract] [Full Text] [Related]
4. Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML-001 trial.
Menezes DL; See WL; Risueño A; Tsai KT; Lee JK; Ma J; Khan R; Prebet T; Skikne B; Beach CL; Thakurta A; Gandhi A
Br J Haematol; 2023 Jun; 201(6):1129-1143. PubMed ID: 36990798
[TBL] [Abstract] [Full Text] [Related]
5. Inhibiting efferocytosis reverses macrophage-mediated immunosuppression in the leukemia microenvironment.
Cruz Cruz J; Allison KC; Page LS; Jenkins AJ; Wang X; Earp HS; Frye SV; Graham DK; Verneris MR; Lee-Sherick AB
Front Immunol; 2023; 14():1146721. PubMed ID: 36960055
[TBL] [Abstract] [Full Text] [Related]
6. Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study.
Manos K; Chong G; Keane C; Lee ST; Smith C; Churilov L; McKendrick J; Renwick W; Blombery P; Burgess M; Nelson NE; Fancourt T; Hawking J; Lin W; Scott AM; Barraclough A; Wight J; Grigg A; Fong CY; Hawkes EA
Leukemia; 2023 May; 37(5):1092-1102. PubMed ID: 36906715
[TBL] [Abstract] [Full Text] [Related]
7. Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasms.
Ivanov D; Milosevic Feenstra JD; Sadovnik I; Herrmann H; Peter B; Willmann M; Greiner G; Slavnitsch K; Hadzijusufovic E; Rülicke T; Dahlhoff M; Hoermann G; Machherndl-Spandl S; Eisenwort G; Fillitz M; Sliwa T; Krauth MT; Bettelheim P; Sperr WR; Koller E; Pfeilstöcker M; Gisslinger H; Keil F; Kralovics R; Valent P
Am J Hematol; 2023 May; 98(5):770-783. PubMed ID: 36814396
[TBL] [Abstract] [Full Text] [Related]
8. Resolution of Melanoma to Programmed Death-1 Blockade but Simultaneous Rapid Progression of Concomitant Chronic Lymphocytic leukemia.
Burgess M; Keane C; Tobin JW; Law SC; Griffin A; Gill D; Ewing AD; Atkinson V; Mollee P; Sabdia MB; Saunders NA; Gandhi MK
Acta Haematol; 2023; 146(2):166-171. PubMed ID: 36273464
[TBL] [Abstract] [Full Text] [Related]
9. Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment.
Geng S; Xu R; Huang X; Li M; Deng C; Lai P; Wang Y; Wu P; Chen X; Weng J; Du X
Front Immunol; 2022; 13():950134. PubMed ID: 36003379
[TBL] [Abstract] [Full Text] [Related]
10. HPV16 Induces Formation of Virus-p62-PML Hybrid Bodies to Enable Infection.
Schweiger L; Lelieveld-Fast LA; Mikuličić S; Strunk J; Freitag K; Tenzer S; Clement AM; Florin L
Viruses; 2022 Jul; 14(7):. PubMed ID: 35891458
[TBL] [Abstract] [Full Text] [Related]
11. Differential Engraftment of Parental A20 PD-L1 WT and PD-L1 KO leukemia Cells in Semiallogeneic Recipients in the Context of PD-L1/PD-1 Interaction and NK Cell-Mediated Hybrid Resistance.
Del Rio ML; Perez-Simon JA; Rodriguez-Barbosa JI
Front Immunol; 2022; 13():887348. PubMed ID: 35795681
[TBL] [Abstract] [Full Text] [Related]
12. Somatic mutation-associated risk index based on lncRNA expression for predicting prognosis in acute myeloid leukemia.
Xu Q; Guo T
Hematology; 2022 Dec; 27(1):659-671. PubMed ID: 35666642
[No Abstract] [Full Text] [Related]
13. Programmed Death Ligand-1 is Frequently Expressed in Primary Acute Myeloid leukemia and B-Acute Lymphoblastic leukemia.
Hamdan SO; Sughayer M; Khader M; Tbakhi A; Khudirat S; Hejazi A; AlRyalat S; Bustami N; Aladily TN
Clin Lab; 2022 Apr; 68(4):. PubMed ID: 35443604
[TBL] [Abstract] [Full Text] [Related]
14. Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL.
Zhang T; Liu H; Jiao L; Zhang Z; He J; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; Zhang H; Wang X
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35365585
[TBL] [Abstract] [Full Text] [Related]
15. Immune-related gene signature predicts clinical outcomes and immunotherapy response in acute myeloid leukemia.
Xu Q; Cao D; Fang B; Yan S; Hu Y; Guo T
Cancer Med; 2022 Sep; 11(17):3364-3380. PubMed ID: 35355427
[TBL] [Abstract] [Full Text] [Related]
16. m6A Regulator-Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration Characterization in Acute Myeloid leukemia.
Du A; Wu X; Gao Y; Jiang B; Wang J; Zhang P; Zhao Q
Front Immunol; 2021; 12():789914. PubMed ID: 34887874
[TBL] [Abstract] [Full Text] [Related]
17. Clinical Features of Disseminated Intravascular Coagulation According to the French-American-British Classification in Patients With Acute leukemia and Thrombomodulin Alfa Treatment-A Cohort Study Using a Postmarketing Surveillance Database.
Yoshinobu S; Honda G; Kawano N; Uchiyama T; Kawasugi K; Madoiwa S; Takezako N; Takayuki I; Wada H
Clin Appl Thromb Hemost; 2021; 27():10760296211054094. PubMed ID: 34870471
[TBL] [Abstract] [Full Text] [Related]
18. Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.
You X; Liu F; Binder M; Vedder A; Lasho T; Wen Z; Gao X; Flietner E; Rajagopalan A; Zhou Y; Finke C; Mangaonkar A; Liao R; Kong G; Ranheim EA; Droin N; Hunter AM; Nikolaev S; Balasis M; Abdel-Wahab O; Levine RL; Will B; Nadiminti KVG; Yang D; Geissler K; Solary E; Xu W; Padron E; Patnaik MM; Zhang J
Blood; 2022 Feb; 139(7):1066-1079. PubMed ID: 34699595
[TBL] [Abstract] [Full Text] [Related]
19. Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia with e1a3 BCR-ABL1 transcript in a Nigerian with sickle cell anemia: a case report.
Ahmed IO; Ochogwu LO; Owojuyigbe TO; Akinola NO; Durosinmi MA
J Med Case Rep; 2021 Oct; 15(1):504. PubMed ID: 34625105
[TBL] [Abstract] [Full Text] [Related]
20. Dual anticancer and antibacterial activities of bismuth compounds based on asymmetric [NN'O] ligands.
Marzano IM; Tomco D; Staples RJ; Lizarazo-Jaimes EH; Gomes DA; Bucciarelli-Rodriguez M; Guerra W; de Souza ÍP; Verani CN; Pereira Maia EC
J Inorg Biochem; 2021 Sep; 222():111522. PubMed ID: 34218087
[TBL] [Abstract] [Full Text] [Related]
[Next]
